Literature DB >> 11491442

Soft tissue sarcomas of the groin: diagnosis, management, and prognosis.

A D Brooks1, W B Bowne, R Delgado, D H Leung, J Woodruff, J J Lewis, M F Brennan.   

Abstract

BACKGROUND: Sott tissue sarcomas (STS) of the groin may present a difficult problem because or misdiagnosis as groin hernia and proximity to major neurovascular structures. We evaluated our management and survival in a large cohort of patients. STUDY
DESIGN: Patients treated between July 1, 1982 and July 1, 1998 with primary or recurrent STS of the groin were included. Groin sarcomas were defined as those tumors within 5 cm of the inguinal crease. Patient, tumor, clinical, and survival data were analyzed using a log rank test and Cox regression.
RESULTS: We treated and followed 88 patients with STS of the groin. The median age was 52 years (range 16 to 86 years) and 55 patients (63%) were male. Disease-specific survival was 72% at 5 years. Tumors tended to be larger than 5 cm (52%), deep (72%), and high-grade (60%). Unfavorable prognostic factors for disease-specific survival were high grade (p < 0.001), neurovascular invasion (p < 0.001), positive margin (p < 0.01), deep depth (p < 0.01), and selection for adjuvant therapy (p < 0.005). Multivariate analysis indicated age greater than 50 years (p < 0.05), high grade (p < 0.001), neurovascular invasion (p < 0.001), and positive microscopic margins (p < 0.001). Fourteen patients (16%) were diagnosed with STS at hernia operation then went on to a definitive operation with no impact on survival. Seventeen patients (19%) had involvement of a major vessel or nerve, and 5 of these ultimately required amputations, 3 for local recurrence.
CONCLUSIONS: High grade, neurovascular invasion, and positive microscopic margins are associated with poor outcomes. The biology of these tumors is similar to other extremity STS, and similar principles of management apply. Even with neurovascular involvement, most patients with primary groin STS do not require amputation.

Entities:  

Mesh:

Year:  2001        PMID: 11491442     DOI: 10.1016/s1072-7515(01)00982-6

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  7 in total

1.  Sarcomas in the groin and inguinal canal--often missed and difficult to manage.

Authors:  T Collin; A V Blackburn; R H Milner; C Gerrand; M Ragbir
Journal:  Ann R Coll Surg Engl       Date:  2010-05       Impact factor: 1.891

Review 2.  Adult inguinoscrotal sarcomas: outcome analysis of 21 cases, systematic review of the literature and meta-analysis.

Authors:  Michael Froehner; Rainer Koch; Arndt Lossnitzer; Rebecca R Schober; Markus Schuler; Manfred P Wirth
Journal:  World J Urol       Date:  2013-07-09       Impact factor: 4.226

3.  Multidisciplinary approach to giant paratesticular liposarcoma.

Authors:  Raquel Sopeña-Sutil; Francesco Silan; Maria Teresa Butron-Vila; Felix Guerrero-Ramos; Emilio Lagaron-Comba; Juan Passas-Martinez
Journal:  Can Urol Assoc J       Date:  2016-09-13       Impact factor: 1.862

4.  Reliability of Margin Assessment after Surgery for Extremity Soft Tissue Sarcoma: The SSG Experience.

Authors:  Clement S Trovik; Sigmund Skjeldal; Henrik Bauer; Anders Rydholm; Nina Jebsen
Journal:  Sarcoma       Date:  2012-06-18

5.  Long-Term Progression-Free Survival in a Patient with Metastatic Leiomyosarcoma of the Inguinal Region Treated with Trabectedin.

Authors:  Ferdinand Haslbauer
Journal:  Case Rep Oncol       Date:  2018-04-19

6.  Inadvertent Inguinal Sarcoma Excision during Hernia Surgery: Outcomes, Gender Analysis, and Prevention.

Authors:  Joshua M Lawrenz; James P Norris; Marcus C Tan; Eric T Shinohara; John J Block; Elizabeth J Davis; Vicki L Keedy; Jennifer L Halpern; Ginger E Holt; Herbert S Schwartz
Journal:  Int J Surg Oncol       Date:  2020-12-07

7.  Worse Survival in Elderly Patients with Extremity Soft-Tissue Sarcoma.

Authors:  Miriam L Hoven-Gondrie; Esther Bastiaannet; Vincent K Y Ho; Barbara L van Leeuwen; Gerrit-Jan Liefers; Harald J Hoekstra; Albert J H Suurmeijer
Journal:  Ann Surg Oncol       Date:  2016-03-08       Impact factor: 5.344

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.